LifeVantage Corporation (NASDAQ: LFVN) – Q3 2026 Earnings
LifeVantage Corporation (NASDAQ: LFVN) – Q3 2026 Earnings
Press release and earnings call link
Section 1: Short Tear Sheeet
LifeVantage is a health and wellness direct-selling company focused on nutrigenomics, which means products designed to support health through nutrition-driven cellular activation. Its revenue comes from independent consultants and customers purchasing products such as Protandim, TrueScience Liquid Collagen, MindBody GLP-1 System, LoveBiome P84 gut-health products, AXIO, skin and hair care, and pet supplements. The company operates in a crowded but large health and wellness market, with its niche built around science-backed supplements and a consultant-driven sales model. The current financial trajectory is negative, with Q3 revenue down 25.2% year over year and adjusted EBITDA cut roughly in half, but management is framing the story as a reset around leadership, field engagement, e-commerce upgrades, new product launches, and capital return.
Quarterly Results
Earnings Release Date: May 6, 2026
Stock Price: $5.49
Market Cap: $69.3 million
Q3 2026 sales of $43.7 million vs $58.4 million in the prior year
Q3 2026 Non-GAAP Adjusted EPS of $0.12 vs $0.26 in the prior year
Q3 2026 GAAP Diluted EPS of $0.11 vs $0.26 in the prior year
Quick Takeaway
LifeVantage is in a turnaround and stabilization phase, focusing on consultant reactivation, e-commerce modernization, new product development, and leadership transition. While the company remains profitable, debt-free, cash-generative, and shareholder-friendly, there are serious concerns about the 25.2% revenue decline, active account weakness, MindBody GLP-1 pressure, and lower-end fiscal 2026 guidance. Execution on Shopify, the VIP consultant program, the October product launch, and the incoming CEO transition will be critical for future performance.
Press Release vs Call Transcript Comparison
The press release makes LifeVantage look like a company with a bad quarter but decent financial discipline. The call makes it look like a company in the middle of a more fundamental reset. That distinction matters. If an investor only reads the release, the story is mostly: revenue down, EBITDA down, guidance near the low end, but balance sheet still clean. If an investor reads the call, the story becomes more nuanced: the company is trying to repair field momentum, modernize the digital platform, bring in a new CEO, launch a new product, and keep returning capital while absorbing GLP-1 category pressure.
The most important investment debate is whether the company’s problems are temporary product-cycle issues or evidence of deeper erosion in the direct-selling model. The call leans toward management’s preferred interpretation: field activity is improving, the platform is being upgraded, leadership is changing, and a new product cycle is coming. But the hard data still favors caution: active accounts are down sharply, revenue is down more than 25%, adjusted EBITDA margin compressed, and MindBody appears to have lost momentum in a competitive GLP-1 environment.
For investors, the next few quarters should be judged less on broad management optimism and more on measurable proof points: consultant count stabilization, active customer trends, Shopify rollout timing, Q4 cash flow, October product launch details, and whether the new CEO can quickly improve field confidence.
Investor Underappreciation Signals
✅Shopify rollout — The e-commerce and back-office upgrade could be more important than it looks because it directly targets customer ordering friction and consultant productivity, yet investors may focus mostly on the current revenue decline until the rollout begins showing measurable conversion or retention benefits.
✅VIP consultant program — The 12-month consultant incentive program is not just a promotion; it is designed to identify growth-oriented field leaders, and investors may overlook it because the current active account numbers still look weak.
✅October product launch — Management effectively pointed to the October convention as the next major product catalyst, and this may be underappreciated because the press release only references new launches in broad guidance language.
✅Cash flow resilience — Despite the sharp revenue decline, management expects continued operating cash generation, which investors may miss if they only focus on lower adjusted EBITDA and reduced guidance.
✅Healthy Glow patent — The call disclosed a U.S. patent for the Healthy Glow Essentials stack, giving the company a stronger science-backed differentiation story that may not be reflected in the headline financials.
✅New CEO reset — Terrence Moorhead’s arrival in August could become a sentiment catalyst because direct-selling turnarounds are highly dependent on leadership credibility, field confidence, and execution discipline.
✅CapEx roll-off potential — Technology spending is temporarily elevated due to Shopify implementation, and investors may underappreciate the potential cash flow lift if development costs decline after rollout.
Section 2: Supplementary Information
Positive Insights
Negative Insights
Tariff Risk
The transcript does not include any discussion of U.S. tariffs, trade policy, tariff-related supply chain risks, production shifts, contract renegotiations, or tariff-related pricing actions. Management did mention higher shipping and warehouse expenses as part of the gross margin decline, but did not connect those costs to tariffs or trade policy.
There were also no comments about tariffs affecting revenue, profitability, market share, competitive advantage, or innovation. Based only on this transcript, tariff risk is not presented as a current management concern, but investors should still verify supply chain exposure in the 10-Q or 10-K because LifeVantage sells physical products and operates internationally.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison (Previous Analysis)
In Q2, LifeVantage’s narrative was that the company had been hit by a major MindBody GLP-1 reset, but management still believed the weakness was manageable because LoveBiome, P84, Shopify, new product launches, international expansion, and capital returns could help offset the pressure. The call was heavy on explaining the competitive shock in GLP-1 and defending the company’s product and portfolio strategy.By Q3, the story had evolved into a broader turnaround. MindBody was still weak, but the company’s bigger focus became rebuilding the direct-selling engine through consultant engagement, a new VIP bonus program, Shopify/back-office upgrades, a future October product launch, and a new CEO arriving in August. The financials remained pressured, but cash flow and balance sheet strength gave management room to execute; the key investor question is now whether the company can stabilize active accounts and prove that the field is reengaging before revenue declines become more structural.
Year-over-year comparison
In Q3 2025, LifeVantage was telling a high-confidence growth story built around MindBody GLP-1. The company had strong revenue growth, improving profitability, rising active accounts, strong subscription behavior, international expansion underway, and management believed MindBody could become an enduring transformational product.
By Q3 2026, that story had flipped into a turnaround narrative. MindBody sales had weakened, active accounts were down, profitability compressed, and guidance was expected near the low end of prior expectations. Management’s new story is that LifeVantage still has valuable assets: a debt-free balance sheet, cash generation, a science-backed portfolio, Shopify modernization, the VIP consultant program, an October product launch, and a new CEO coming in August. The investment question has changed from “how big can MindBody get?” to “can management rebuild consultant momentum and stabilize revenue before the decline becomes structural?”